Rosenblatt raises Zscaler stock price target on growth visibility

Rosenblatt raised its Zscaler price target to $250 from $200 and reiterated Buy, implying about 24% upside, citing improved visibility and durability rather than higher near-term results. At Investor Day, management outlined a target of more than $8 billion in annual recurring revenue by FY2031, versus about $3.8 billion at FY2026 year-end; three newer product lines grew ARR 60% combined in FY2026. Zscaler maintained FY2027 revenue guidance of $3.91 billion-$3.94 billion and adjusted EPS guidance of $4.86-$4.90; other firms also raised price targets.

Analysis

The investor-day case is a durability argument, not a near-term earnings-revision story: the FY2031 ARR ambition largely extends the growth pace already implied by FY2027 guidance. That makes execution—and the conversion of new-product ARR into renewals, cross-sell and cash generation—more important than the headline target. The reported 60% growth across newer offerings is encouraging, but without product-level scale and retention data it does not establish that these lines can sustain consolidated growth as they mature.

A second-order risk is that security budgets are not expanding as fast as vendors’ AI-security pitches. Zscaler may gain share, but Microsoft, Palo Alto Networks and CrowdStrike can bundle or cross-sell adjacent capabilities, pressuring customer acquisition costs and deal economics. A 77% gross margin is not proof that incremental growth will translate into operating leverage; sales capacity, implementation and product investment still matter.

The stock’s substantial recent run and cluster of target increases raise the bar for incremental buyers. Analyst targets are not independent evidence of demand, and the stated $250 target is about 18% above the article’s $212.25 price—not 24%—so the cited upside framing should be checked. Over 1–3 months, watch billings/ARR commentary, remaining performance obligations, renewal and cross-sell evidence, and any guidance change. Over 6–18 months, the thesis is falsified by sustained growth deceleration, weaker retention, or growth accompanied by deteriorating operating leverage. No valuation or options data are provided to justify a high-conviction entry today.

Key Decisions for Investors

• Do not chase the analyst-target cycle at the current level. For new exposure, wait for a pullback or for the next results to verify that newer products are contributing meaningful ARR and that customer expansion is holding up.
• For existing ZS exposure, keep the position sized to execution risk rather than treating the FY2031 ARR goal as secured; reassess on any downward guidance revision, weakening renewal/cross-sell indicators, or growth without improving operating leverage.
• Set an alert for product-level ARR or comparable adoption disclosure, retention, billings/RPO trends and sales-efficiency commentary. These are the missing checks needed to distinguish durable platform expansion from optimistic long-range targets.
• Watch competitive discounting and bundling by Microsoft, Palo Alto Networks and CrowdStrike as a downside catalyst; relative product wins and deal economics matter more than the aggregate AI-security narrative.